Dalbavancin is a semisynthetic glycopeptide antibiotic.1 It inhibits the growth of Gram-positive bacteria in vitro, including S. pneumoniae, S. pyogenes, vancomycin-sensitive Enterococcus species, and various methicillin-resistant staphylococci (MIC50s = 0.03, ≤0.002, 0.13, and 0.03-0.13 mg/L, respectively). Dalbavancin increases survival in mouse models of infection with S. aureus and S. pneumoniae (ED50s = 0.08 and 0.56 mg/kg, respectively). This product is a mixture of five closely related components, dalbavancin A0, A1, B0, B1, and B2, with dalbavancin B0 being the major component (≥75%). Formulations containing dalbavancin have been used in the treatment of bacterial skin infections caused by Gram-positive bacteria.
1.Candiani, G., Abbondi, M., Borgonovi, M., et al.In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibioticJ. Antimicrob. Chemother.44(2)179-192(1999)